et al Cerebrovascular accidents: rates and risk factors. Blood.1998;91:288-294.
et al The spectrum of brain MR abnormalities in sickle cell disease: a report from the Cooperative Study of Sickle Cell Disease. AJNR Am J Neuroradiol.1996;17:965-972.
et al Cognitive functioning and brain magnetic resonance imaging in children with sickle cell disease. Pediatrics.1996;97:864-870.
TE Cerebral infarction in sickle cell anemia: mechanism based on CT and MRI. Neurology.1988;38:1012-1017.
PRF Major intracerebral involvement in sickle cell disease. Surg Neurol.1980;14:291-295.
JW Cerebral infarction secondary to sickle cell disease: arteriographic findings. AJR Am J Roentgenol.1980;134:1209-1212
HR Moyamoya in children with sickle cell anemia and cerebrovascular occlusion. J Pediatr.1978;93:808-810.
A Cerebrovascular moyamoya disease: disease showing abnormal net-like vessels in the base of the brain. Arch Neurol.1969;20:288-299.
JS Sickle cell anemia and central nervous system infarction: a neuropathological study. Ann Neurol.1986;20:684-690.
MJD Cerebrovascular disease in sickle cell anemia: a clinical pathological and radiological correlation. Stroke.1978;9:45-52.
et al The natural history of stroke in sickle cell disease. Am J Med.1978;65:461-471.
et al Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease. Blood.1984;63:162-169.
et al Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr.1995;126:896-899.
E Efficacy of transfusion for one to two years in patients with sickle cell disease and cerebrovascular accidents. J Pediatr.1980;96:205-208.
E Strokes and their management in sickle cell disease.
W, ed. Comparative Clinical Aspects of Sickle Cell Disease. Amsterdam, the Netherlands: Elsevier Science Publishers; 1982:101-111.
OL Discontinuation of long-term transfusion therapy in patients with sickle cell disease and stroke. J Pediatr.1997;131:757-760.
et al High risk of recurrent stroke after discontinuation of five to twelve years of transfusion therapy in patients with sickle cell disease. J Pediatr.1991;118:377-382.
CD Management and Therapy of Sickle Cell Disease. Washington, DC: Public Health Service, US Dept of Health and Human Services; 1992:22. NIH publication 92-2117.
et al Prevention of first stroke by transfusions in children with sickle sell anemia and abnormal results on transcranial ultrasonography. N Engl J Med.1998;339:5-11.
National Heart, Lung, and Blood Institute Not Available Clinical Alert. Washington, DC: US Dept of Health and Human Services; September18 , 1997.
DG Transfusion management of sickle cell disease. Blood.1993;81:1109-1123.
et al Pain in sickle cell disease: rates and risk factors. N Engl J Med.1991;325:11-16.
et al Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. N Engl J Med.1995;332:1317-1322.
WH Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood.1999;94:3022-3026.
FB Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. Br J Haematol.1999;105:491-496.
et al Decrease of very late activation of antigen-4 and CD-36 on reticulocytes in sickle cell patients treated with hydroxyurea. Blood.1997;89:2554-2559.
et al Safety of hydroxyurea in children with sickle cell disease: results of the HUG-KIDS Study, a phase I/II trial: Pediatric Hydroxyurea Group. Blood.1999;94:1550-1554.
et al Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Blood.2000;95:1918-1924.
MC Bone marrow transplantation for sickle cell disease: where do we go from here? J Pediatr Hematol Oncol.1999;21:467-474.
F Results and current indications of bone marrow allograft in sickle cell disease. Pathol Biol (Paris).1999;47:59-64.
et al Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke.1996;27:1711-1718.
et al Preventing ischemic stroke in patients with prior stroke and transient ischemic attack: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke.1999;30:1991-1994.
JP Encephaloduroarteriosynangiosis in a child with sickle cell disease and moyamoya disease. Pediatr Neurol.1996;14:226-230.
et al Antiphospholipid antibodies, proteins C and S and coagulation changes in sickle cell disease. J Lab Clin Med.1999;134:352-362.
OL Homocysteine in sickle cell disease: relationship to stroke. Am J Med.1997;103:192-196.